Business Context and Reporting Period
This Form 8-K Current Report is filed by Teva Pharmaceutical Industries Limited on May 20, 2025. The filing discloses the pricing of a new senior notes offering and the execution of an underwriting agreement. The transaction involves three separate issuers: Teva Pharmaceutical Finance Netherlands II B.V., III B.V., and IV B.V., with the Company acting as guarantor.
Key Financial Metrics and Transaction Details
The Company announced the pricing of €2.2 billion in aggregate principal amount of senior notes across three tranches. The specific terms are as follows:
- Euro Notes: €1,000,000,000 aggregate principal, 4.125% coupon, due 2031. Priced at 99.349% of principal.
- 2032 USD Notes: $500,000,000 aggregate principal, 6.000% coupon, due 2032. Priced at 99.256% of principal.
- 2030 USD Notes: $700,000,000 aggregate principal, 5.750% coupon, due 2030. Priced at 99.418% of principal.
The sale of these securities is expected to close on May 28, 2025. The underwriters include BNP PARIBAS, BofA Securities, HSBC, Intesa Sanpaolo, and J.P. Morgan SE.
Material Changes
This filing represents a material change in the Company's capital structure through the issuance of new long-term debt. The filing does not provide comparative financial metrics (revenue, profit, cash flow) against prior periods as it is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) regarding the pricing but does not contain explicit forward-looking guidance, management commentary on operational outlook, or specific risk factors within the text of this 8-K. The offering is registered under the Securities Act of 1933 via a Form S-3ASR filed on February 7, 2025. The underwriting agreement includes customary representations, warranties, indemnification, and contribution provisions.
Investor Verification Checklist
- Verify the final closing date of the transaction (expected May 28, 2025) and the actual proceeds received after underwriting discounts.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, redemption rights, and default provisions.
- Confirm the use of proceeds as detailed in the accompanying press release (Exhibit 99.1) and the prospectus supplement.
- Assess the impact of the new debt load on the Company's leverage ratios and liquidity position.